5paisa Capital gets partial relief of ₹40 crore on AY 2023-24 tax appeal

Legal

Blacklitt Research29 October 20262 min read

A calculator on a table next to a laptop. — Photo by Jakub Żerdzicki on Unsplash (Unsplash License). Illustrative image.

5paisa Capital (NSE: 5PAISA) has had its appeal partly allowed by the CIT(A) against an NFAC assessment order for AY 2023-24, with relief of ₹40.03 crore of the ₹42.90 crore in disputed additions and disallowances, it said in a filing on 29 Oct 2026.

Key highlights

Relief granted by CIT(A): ₹40.03 crore
Total disputed additions and disallowances: ₹42.90 crore
Disallowance sustained: ₹2.87 crore
CIT(A) order dated 28 Oct 2026

The appeal in numbers

Item	Detail
Assessment year	AY 2023-24
Assessment order	Passed by NFAC, Delhi, u/s 143(3) r.w.s.144B of the Income-tax Act, 1961
Appeal forum	CIT(A)-54, Mumbai
CIT(A) order date	28 Oct 2026
Disputed additions and disallowances	₹42.90 crore
Relief granted	₹40.03 crore
Disallowance sustained	₹2.87 crore
Compensation or penalty	None imposed

Relief on most of the disputed amount

The CIT(A) order dated 28 Oct 2026 granted relief of ₹40.03 crore on the ₹42.90 crore of additions and disallowances made in the AY 2023-24 assessment order. The company says the order is substantially favourable to it.

The filing states that no compensation or penalty has been imposed.

₹2.87 crore remains disallowed

The disallowance of ₹2.87 crore is sustained. The company says it has sufficient documentation in support of the remaining disallowance and will take the necessary action before the Adjudicating Authority within the prescribed timelines.

What the appeal order means for 5paisa Capital's shareholders

The order reduces the amount still in dispute to ₹2.87 crore on the figures in the filing. The filing does not say what tax demand or refund, if any, arises from the order, how it affects the company's results, or how long the Adjudicating Authority process will take.

The company's next step is action before the Adjudicating Authority within the prescribed timelines.

Reference: Original filing (PDF)

Sign up to continue reading

Create a free account to read the rest of this article and the analysis that follows.

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.